UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3093-3099

2012

Volltextzugriff (PDF)

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

British journal of haematology, 2016-11, Vol.175 (3), p.410-418

2016

Volltextzugriff (PDF)

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4365-4370

2009

Volltextzugriff (PDF)

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Haematologica (Roma), 2015-06, Vol.100 (6), p.e240

2015

Volltextzugriff (PDF)

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non‐Hodgkin lymphoma

British journal of haematology, 2016-05, Vol.173 (3), p.432-443

2016

Volltextzugriff (PDF)

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B‐cell non‐Hodgkin lymphomas. A Norwegian multi centre phase II study

British journal of haematology, 2011-03, Vol.152 (5), p.600-610

2011

Volltextzugriff (PDF)

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma

Acta oncologica, 2014-05, Vol.53 (5), p.680-687

2014

Volltextzugriff (PDF)

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era

Leukemia & lymphoma, 2014-10, Vol.55 (10), p.2319-2327

2014

Volltextzugriff (PDF)

Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987–2008

Tidsskrift for den Norske Lægeforening, 2013, Vol.133 (16), p.1704-1709

2013

Volltextzugriff (PDF)

Høydosebehandling med autolog stamcellestøtte ved lymfom – fra utprøvende til standard behandling

Tidsskrift for den Norske Lægeforening, 2013, Vol.133 (16), p.1735-1739

2013

Volltextzugriff (PDF)

Peripheral T-cell lymphoma with involvement of the expanded mantle zone

Virchows Archiv : an international journal of pathology, 2006-07, Vol.449 (1), p.78-87

2006

Volltextzugriff (PDF)

Clonal deletion of thymocytes as a tumor escape mechanism

International journal of cancer, 1998-10, Vol.78 (2), p.216-222

1998

Volltextzugriff (PDF)

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

Blood, 2016-12, Vol.128 (22), p.1830-1830

2016

Volltextzugriff (PDF)

A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8598-8598

2015

Volltextzugriff (PDF)

Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)

British journal of haematology, 2012-09, Vol.158 (6), p.815

2012

Volltextzugriff (PDF)

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant

Blood, 2011-11, Vol.118 (21), p.4110-4110

2011

Volltextzugriff (PDF)

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment

Tidsskrift for den Norske Lægeforening, 2013-09, Vol.133 (16), p.1735-1739

2013

Volltextzugriff (PDF)

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008

Tidsskrift for den Norske Lægeforening, 2013-09, Vol.133 (16), p.1704-1709

2013

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(32)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(17)
Female
(15)
Male
(15)
Hematology
(14)
Medicin Och Hälsovetenskap
(14)
Middle Aged
(13)
Adult
(12)
Aged
(11)
Biological And Medical Sciences
(10)
Clinical Medicine
(10)
Klinisk Medicin
(10)
Medical And Health Sciences
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Medical Sciences
(9)
Transplantation, Autologous
(9)
Treatment Outcome
(9)
Hematologi
(8)
Hematologic And Hematopoietic Diseases
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non‐Hodgkin lymphoma

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B‐cell non‐Hodgkin lymphomas. A Norwegian multi centre phase II study

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era

Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987–2008

Høydosebehandling med autolog stamcellestøtte ved lymfom – fra utprøvende til standard behandling

Peripheral T-cell lymphoma with involvement of the expanded mantle zone

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Clonal deletion of thymocytes as a tumor escape mechanism

Response at Interim Evaluation Predicts Survival after Autologous Stem Cell Transplantation in Nodal Peripheral T-Cell Lymphoma; A Nordic Lymphoma Group Study

A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma

Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)

Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant

90y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008

Suchergebnisse filtern